JP2011513420A - レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置 - Google Patents

レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置 Download PDF

Info

Publication number
JP2011513420A
JP2011513420A JP2010549844A JP2010549844A JP2011513420A JP 2011513420 A JP2011513420 A JP 2011513420A JP 2010549844 A JP2010549844 A JP 2010549844A JP 2010549844 A JP2010549844 A JP 2010549844A JP 2011513420 A JP2011513420 A JP 2011513420A
Authority
JP
Japan
Prior art keywords
alkyl
hydroxy
aryl
haloalkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010549844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513420A5 (enExample
Inventor
ガイ エム． ミラー，
Original Assignee
エジソン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エジソン ファーマシューティカルズ， インコーポレイテッド filed Critical エジソン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2011513420A publication Critical patent/JP2011513420A/ja
Publication of JP2011513420A5 publication Critical patent/JP2011513420A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010549844A 2008-03-05 2009-03-04 レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置 Withdrawn JP2011513420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6833008P 2008-03-05 2008-03-05
US19119808P 2008-09-05 2008-09-05
PCT/US2009/035996 WO2009111543A2 (en) 2008-03-05 2009-03-04 Treatment of hearing and balance impairments with redox-active therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014016459A Division JP6131200B2 (ja) 2008-03-05 2014-01-31 レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置

Publications (2)

Publication Number Publication Date
JP2011513420A true JP2011513420A (ja) 2011-04-28
JP2011513420A5 JP2011513420A5 (enExample) 2013-04-04

Family

ID=41056624

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010549844A Withdrawn JP2011513420A (ja) 2008-03-05 2009-03-04 レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置
JP2014016459A Active JP6131200B2 (ja) 2008-03-05 2014-01-31 レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置
JP2015160272A Withdrawn JP2015205938A (ja) 2008-03-05 2015-08-17 レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置
JP2017151442A Pending JP2017193590A (ja) 2008-03-05 2017-08-04 レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014016459A Active JP6131200B2 (ja) 2008-03-05 2014-01-31 レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置
JP2015160272A Withdrawn JP2015205938A (ja) 2008-03-05 2015-08-17 レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置
JP2017151442A Pending JP2017193590A (ja) 2008-03-05 2017-08-04 レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置

Country Status (5)

Country Link
US (3) US20110046156A1 (enExample)
EP (1) EP2262519A4 (enExample)
JP (4) JP2011513420A (enExample)
CA (1) CA2717741C (enExample)
WO (1) WO2009111543A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018500326A (ja) * 2014-12-16 2018-01-11 バイオエレクトロン テクノロジー コーポレイション （ｒ）−２−ヒドロキシ−２−メチル−４−（２，４，５−トリメチル−３，６−ジオキソシクロヘキサ−１，４−ジエニル）ブタンアミドの多形性形態および非晶質形態
JP2018531250A (ja) * 2015-10-08 2018-10-25 コンドリオン アイピー ビー．ブイ．Ｋｈｏｎｄｒｉｏｎ Ｉｐ Ｂ．Ｖ． ミトコンドリア疾患を治療する新規化合物
JP2022074312A (ja) * 2020-11-04 2022-05-18 国立大学法人 東京大学 騒音性難聴の予防剤

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065099A1 (en) 2003-09-19 2005-03-24 Gail Walkinshaw Treatment of mitochondrial diseases
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
SI2220030T1 (sl) 2007-11-06 2016-04-29 Edison Pharmaceuticals, Inc. Derivati 4-(p-kuinonil)-2-hidroksibutanamida za zdravljenje mitohondrijskih bolezni
WO2009089224A1 (en) * 2008-01-08 2009-07-16 Edison Pharmaceuticals, Inc. (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
US8716527B2 (en) 2008-03-05 2014-05-06 Edison Pharmaceuticals, Inc. 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
BRPI0918139B1 (pt) 2008-09-10 2024-04-30 Ptc Therapeutics, Inc Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2974482C (en) 2008-10-28 2019-10-29 Bioelectron Technology Corporation High purity alpha tocotrienol quinone and processes for preparing same
EP2424495B1 (en) 2009-04-28 2018-01-17 Bioelectron Technology Corporation Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
PL2470168T3 (pl) * 2009-08-26 2018-06-29 Bioelectron Technology Corporation Sposoby zapobiegania i leczenia niedokrwienia mózgu
EP2519232A1 (en) * 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
US20130116336A1 (en) * 2010-04-06 2013-05-09 William D. Shrader Treatment of ataxia telangiectasia
EP2720689A4 (en) 2011-06-14 2014-11-26 Edison Pharmaceuticals Inc CATECHOL DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATIVE STRESS
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
EP2982382A1 (en) 2014-08-04 2016-02-10 Sensorion Compounds for preventing ototoxicity
EP3284055B1 (en) 2015-04-16 2020-08-19 Honeywell International Inc. Multi-sensor input analysis for improved safety
EP3390377A1 (en) 2015-12-16 2018-10-24 BioElectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
KR101785455B1 (ko) 2016-03-16 2017-11-20 전남대학교산학협력단 귀리 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약제학적 조성물
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
CA3116866A1 (en) 2018-10-17 2020-04-23 Ptc Therapeutics, Inc. 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating .alpha.-synucleinopathies, tauopathies, and other disorders
KR102177610B1 (ko) * 2019-03-28 2020-11-11 단국대학교 천안캠퍼스 산학협력단 청각세포와의 공배양을 이용한 배아줄기세포의 내이 세포로의 분화 방법
CN118175991A (zh) 2021-07-08 2024-06-11 Ptc医疗公司 包含2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮的药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500091A (ja) * 1992-05-28 1996-01-09 モナッシュ・ユニバーシティー 治療用組成物
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1040908A (en) 1910-09-06 1912-10-08 George E Dunton Composition of matter for use in removing grease, &c., from the molds used in the art of electrotyping.
US1038708A (en) 1911-11-01 1912-09-17 Hipolit Zielinski Wrench.
JPS5938203B2 (ja) * 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US4637402A (en) 1980-04-28 1987-01-20 Adelman Roger A Method for quantitatively measuring a hearing defect
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US5546956A (en) 1992-04-04 1996-08-20 Medical Research Council Testing hearing
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
DE4402380A1 (de) 1994-01-27 1995-08-03 Hans Peter Prof Dr Med Zenner Implantierbares Dosiersystem
ES2209118T3 (es) * 1997-02-12 2004-06-16 Mse Pharmazeutika Gmbh Empleo de 2,3-dimetoxi-5-metil-6-decaprenil-1,4-benzoquinona en el tratamiento del zumbido de oidos.
US6228891B1 (en) * 1997-02-12 2001-05-08 Mse Pharmazeutika Gmbh Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
EP1351912A2 (en) * 2000-12-21 2003-10-15 Cancer Research Ventures Limited Substituted stilbenes, their reactions and anticancer activity
US7700134B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Prevention of cisplatin induced deafness
US20030229333A1 (en) 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
EP1454627A1 (en) * 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
US20040204471A1 (en) 2003-03-20 2004-10-14 Pharmacia Corporation Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
JP2008503579A (ja) * 2004-06-21 2008-02-07 ハッチソン メディファーマ エンタープライジズ リミテッド 癌の化学療法
US20070021497A1 (en) * 2005-07-11 2007-01-25 The Fruitful Yield Vitamin e compositions
US7786100B2 (en) * 2006-03-20 2010-08-31 The Regents Of The University Of Michigan Composition and method of treating hearing loss
SI2220030T1 (sl) * 2007-11-06 2016-04-29 Edison Pharmaceuticals, Inc. Derivati 4-(p-kuinonil)-2-hidroksibutanamida za zdravljenje mitohondrijskih bolezni
WO2009089224A1 (en) * 2008-01-08 2009-07-16 Edison Pharmaceuticals, Inc. (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
US8716527B2 (en) * 2008-03-05 2014-05-06 Edison Pharmaceuticals, Inc. 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500091A (ja) * 1992-05-28 1996-01-09 モナッシュ・ユニバーシティー 治療用組成物
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US20070225261A1 (en) * 2006-02-22 2007-09-27 Miller Guy M Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MITOCHONDRION, vol. 4, JPN6013037634, 2004, pages 675 - 694, ISSN: 0002596792 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018500326A (ja) * 2014-12-16 2018-01-11 バイオエレクトロン テクノロジー コーポレイション （ｒ）−２−ヒドロキシ−２−メチル−４−（２，４，５−トリメチル−３，６−ジオキソシクロヘキサ−１，４−ジエニル）ブタンアミドの多形性形態および非晶質形態
JP2020111582A (ja) * 2014-12-16 2020-07-27 バイオエレクトロン テクノロジー コーポレイション （ｒ）−２−ヒドロキシ−２−メチル−４−（２，４，５−トリメチル−３，６−ジオキソシクロヘキサ−１，４−ジエニル）ブタンアミドの多形性形態および非晶質形態
JP2021185199A (ja) * 2014-12-16 2021-12-09 ピーティーシー セラピューティクス， インコーポレイテッド （ｒ）−２−ヒドロキシ−２−メチル−４−（２，４，５−トリメチル−３，６−ジオキソシクロヘキサ−１，４−ジエニル）ブタンアミドの多形性形態および非晶質形態
JP7111759B2 (ja) 2014-12-16 2022-08-02 ピーティーシー セラピューティクス， インコーポレイテッド （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態
JP2022116352A (ja) * 2014-12-16 2022-08-09 ピーティーシー セラピューティクス， インコーポレイテッド （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態
JP7277061B2 (ja) 2014-12-16 2023-05-18 ピーティーシー セラピューティクス， インコーポレイテッド （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態
JP7541546B2 (ja) 2014-12-16 2024-08-28 ピーティーシー セラピューティクス， インコーポレイテッド （ｒ）－２－ヒドロキシ－２－メチル－４－（２，４，５－トリメチル－３，６－ジオキソシクロヘキサ－１，４－ジエニル）ブタンアミドの多形性形態および非晶質形態
JP2018531250A (ja) * 2015-10-08 2018-10-25 コンドリオン アイピー ビー．ブイ．Ｋｈｏｎｄｒｉｏｎ Ｉｐ Ｂ．Ｖ． ミトコンドリア疾患を治療する新規化合物
JP2020073524A (ja) * 2015-10-08 2020-05-14 コンドリオン アイピー ビー．ブイ．Ｋｈｏｎｄｒｉｏｎ Ｉｐ Ｂ．Ｖ． ミトコンドリア疾患を治療する新規化合物
JP2022074312A (ja) * 2020-11-04 2022-05-18 国立大学法人 東京大学 騒音性難聴の予防剤
JP7531808B2 (ja) 2020-11-04 2024-08-13 国立大学法人 東京大学 騒音性難聴の予防剤

Also Published As

Publication number Publication date
US20110046156A1 (en) 2011-02-24
JP6131200B2 (ja) 2017-05-17
WO2009111543A3 (en) 2009-12-30
JP2015205938A (ja) 2015-11-19
JP2014077019A (ja) 2014-05-01
EP2262519A4 (en) 2011-03-23
US20140249160A1 (en) 2014-09-04
US20180200248A1 (en) 2018-07-19
EP2262519A2 (en) 2010-12-22
JP2017193590A (ja) 2017-10-26
CA2717741C (en) 2018-04-03
WO2009111543A2 (en) 2009-09-11
CA2717741A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
JP6131200B2 (ja) レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置
US10966962B2 (en) Method for treating neurodegenerative diseases
JP2021502403A (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
US11116773B2 (en) Method of treating dementia
KR102860817B1 (ko) 트라디피턴트에 의한 치료 방법
US12138269B2 (en) Method of treating dementia
CN107847489A (zh) 用于治疗听力损失的司琼类钙调神经磷酸酶抑制剂
JP2018076332A (ja) （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法
JP2022536017A (ja) 精神障害、行動障害、認知障害を処置する方法
AU2015317877A1 (en) Methods and compositions for treating psychotic disorders
WO2001008705A1 (en) Remedies for neurogenic pains
CN114246949B (zh) Ulk1激活剂在预防和/治疗听力损伤中的应用
CN104244950B (zh) 含有西洛他唑及银杏叶提取物作为有效成分的听觉障碍预防或治疗用药物组合物
US20240252467A1 (en) Treatment of mental illness via administration of buntanetap and analogues thereof
KR20180129923A (ko) 귀 장애의 치료에 사용하기 위한 (+)-아자세트론
JP7158723B2 (ja) 耳疾患の処置における使用のための（＋）－アザセトロン
RU2554813C1 (ru) Способ лечения и профилактики нейросенсорной тугоухости и шумовых эффектов внутреннего уха, связанных с воздействием производственного шума
JPWO2007100079A1 (ja) 三環性トリアゾロベンゾアゼピン誘導体を含有する、アレルギー性眼疾患またはアレルギー性鼻疾患の予防または治療剤
WO2022112511A1 (en) Pharmaceutical composition for treatment of inner ear disorders through local administration in the tympanic area
KR20230083272A (ko) 신경병성 통증의 국소 치료에 사용하기 위한 메피라민
Gheorghe et al. Treatment with selegiline in Alzheimer's disease—SPECT evaluations
Paparrigopoulos et al. Idiopathic vs symptomatic REM sleep behavior disorder: A report of two cases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131029

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140811

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141008

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20141121

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20141226